Taking into account the potential role of TNF-ɑ in the development of obstetric complications, a study is being carried out with an anti-TNF (certolizumab) to determine if it is possible to reduce the risk of adverse events in patients with obstetric APS and high-risk antiphospholipid antibody profile (NCT03152058). This evidence concerns the gene TNF and autoimmune polyendocrinopathy.